US 11,744,872 B2
Cyclosporine formulations for use in the prevention or treatment of pulmonary chronic graft rejection
Martin Knoch, Garmisch-Partenkirchen (DE); and Oliver Denk, Münsing (DE)
Assigned to BREATH THERAPEUTICS GMBH, Munich (DE)
Filed by BREATH THERAPEUTICS GMBH, Munich (DE)
Filed on Oct. 30, 2020, as Appl. No. 17/86,254.
Application 17/086,254 is a continuation of application No. 15/558,102, granted, now 10,857,198, previously published as PCT/EP2016/055609, filed on Mar. 15, 2016.
Claims priority of application No. 15020035 (EP), filed on Mar. 16, 2015.
Prior Publication US 2021/0046150 A1, Feb. 18, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 38/13 (2006.01); A61K 9/00 (2006.01); A61K 9/127 (2006.01); A61K 9/19 (2006.01); A61K 47/26 (2006.01); A61K 45/06 (2006.01)
CPC A61K 38/13 (2013.01) [A61K 9/0053 (2013.01); A61K 9/0078 (2013.01); A61K 9/127 (2013.01); A61K 9/19 (2013.01); A61K 45/06 (2013.01); A61K 47/26 (2013.01)] 21 Claims
OG exemplary drawing
 
1. A method of preventing or treating pulmonary chronic graft rejection in single lung transplanted patients comprising administering to a patient in need thereof a liposomal cyclosporine liquid formulation as an aerosol for inhalation;
wherein the formulation contains the cyclosporine at a concentration of 1 mg/mL up to 5 mg/ml and wherein the volume of a unit dose of the formulation is 1 to 3 mL,
wherein the patient is a human patient of higher age, and wherein the patient is co-administered one or more active ingredients used in standard immunosuppressive therapy after lung transplantation, wherein the one or more active ingredients constitute a standard of care systemic immunosuppression regimen.